The CARES-009 phase 2/3 trial investigated the efficacy of perioperative camrelizumab plus rivoceranib in patients with hepatocellular carcinoma (HCC) at intermediate or high risk of relapse. The trial aimed to determine whether combining immunotherapy and targeted therapy before and after surgery could improve outcomes compared to surgery alone.
The CARES-009 phase 2/3 trial investigated the efficacy of perioperative camrelizumab plus rivoceranib in patients with hepatocellular carcinoma (HCC) at intermediate or high risk of relapse. The trial aimed to determine whether combining immunotherapy and targeted therapy before and after surgery could improve outcomes compared to surgery alone. In the study, 294 patients were randomly assigned to two groups: one receiving perioperative therapy (neoadjuvant and adjuvant camrelizumab plus rivoceranib) and the other undergoing surgery alone.
Results showed that patients in the perioperative therapy group had significantly improved event-free survival (EFS) with a median of 42.1 months compared to 19.4 months in the surgery-alone group (HR 0.59, p=0.0040). However, adverse events of grade 3 or higher occurred in 38% of patients receiving perioperative therapy, including two treatment-related deaths during neoadjuvant therapy. This trial highlights the potential benefits of perioperative immunotherapy but underscores the importance of managing associated risks.
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is now the fastest-growing cause of hepatocellular carcinoma (HCC). Because a substantial proportion of MASLD-related HCC develops before cirrhosis, better tools are needed to identify high-risk patients who...
Introduction: The HIMALAYA trial established durvalumab plus tremelimumab (STRIDE) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). However, many real-world patients do not meet the strict eligibility criteria of clinical trials. This multicenter study...
Introduction: Prognosis in unresectable hepatocellular carcinoma (HCC) depends not only on tumor burden but also on liver function and nutritional status. This study evaluated the prognostic value of ALBI grade, EZ-ALBI grade, and sarcopenia in...
Introduction: Hepatocellular carcinoma (HCC) surveillance enables earlier diagnosis and improves survival. This largest UK multicenter study evaluated how patients are diagnosed in routine clinical practice and identified major gaps in the surveillance pathway. Why was...
Introduction: Selective internal radiation therapy (SIRT) using yttrium-90 (Y90) glass microspheres is an established locoregional treatment for hepatocellular carcinoma (HCC), but guideline recommendations remain inconsistent. This large prospective multicenter study evaluated the real-world effectiveness, safety,...
Introduction: Atezolizumab–bevacizumab (A/B) and durvalumab–tremelimumab (STRIDE) are preferred first-line treatments for advanced hepatocellular carcinoma (HCC). Because bevacizumab inhibits VEGF, concerns remain regarding bleeding and thromboembolic complications in patients with underlying cirrhosis and portal hypertension. Why...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.